Neuroloxía
Servizo
![Foto de Neuroloxía](/img/noimage.png)
![Foto de Hospital Universitario Nuestra Señora de Candelaria](/img/noimage_org.png)
Hospital Universitario Nuestra Señora de Candelaria
Santa Cruz de Tenerife, EspañaPublicacións en colaboración con investigadores/as de Hospital Universitario Nuestra Señora de Candelaria (24)
2024
-
Assessing illness-related uncertainty in relapsing-remitting multiple sclerosis: A psychometric analysis of the Mishel Uncertainty of Illness Scale
Multiple Sclerosis Journal - Experimental, Translational and Clinical, Vol. 10, Núm. 2
-
Description of clinical and genetic features of 122 patients included in the Spanish Pompe registry
Neuromuscular Disorders, Vol. 34, pp. 1-8
2023
-
Effectiveness and Safety of Teriflunomide in Relapsing–Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study
Neurology and Therapy, Vol. 12, Núm. 6, pp. 2177-2193
-
Epidemiology of ataxia and hereditary spastic paraplegia in Spain: a cross-sectional study
Neurologia, Vol. 38, Núm. 6, pp. 379-386
2022
-
Consensus on early detection of disease progression in patients with multiple sclerosis
Frontiers in Neurology, Vol. 13
-
Consensus statement on the use of alemtuzumab in daily clinical practice in Spain
Neurologia, Vol. 37, Núm. 8, pp. 615-630
-
Expert-Agreed Practical Recommendations on the Use of Cladribine
Neurology and Therapy
2020
-
New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab
Frontiers in Neurology, Vol. 11
-
New genotype-phenotype correlations in a large European cohort of patients with sarcoglycanopathy
Brain, Vol. 143, Núm. 9, pp. 2696-2708
2019
-
PDGF-BB serum levels are decreased in adult onset Pompe patients
Scientific Reports, Vol. 9, Núm. 1
2018
2017
-
Assessment of plasma chitotriosidase activity, CCL18/PARC concentration and NP-C suspicion index in the diagnosis of Niemann-Pick disease type C: A prospective observational study
Journal of Translational Medicine, Vol. 15, Núm. 1
-
Erratum to “Safety, efficacy and outcome-related factors of perampanel over 12months in a real-world setting: The FYDATA study” [Epilepsy Res. (2016) 126 (201–210)] (S0920121116301218)(10.1016/j.eplepsyres.2016.08.001)
Epilepsy Research
2016
-
Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: The FYDATA study
Epilepsy Research, Vol. 126, pp. 201-210
2015
-
Consenso español actualizado sobre el uso del natalizumab (Tysabri®)-2013
Neurologia, Vol. 30, Núm. 5, pp. 302-314
2014
-
Long-term safety and efficacy of eslicarbazepine acetate in patients with focal seizures: Results of the 1-year ESLIBASE retrospective study
Epilepsy Research, Vol. 108, Núm. 7, pp. 1243-1252
2013
-
Revisión de las novedades presentadas en el XXVIII Congreso del Comité Europeo para el Tratamiento e Investigación en Esclerosis Múltiple (ECTRIMS) (I)
Revista de Neurologia, Vol. 57, Núm. 5, pp. 217-229
-
Revisión de las novedades presentadas en el XXVIII Congreso del Comité Europeo para el Tratamiento e Investigación en Esclerosis Múltiple (ECTRIMS) (II)
Revista de Neurologia, Vol. 57, Núm. 6, pp. 269-281
-
Revisión de las novedades presentadas en el XXVIII congreso del comité europeo para el tratamiento e investigación en esclerosis múltiple (ECTRIMS) (III)
Revista de Neurologia, Vol. 57, Núm. 7, pp. 317-329